NCT03937869View on ClinicalTrials.gov

Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

November 5, 2020

Study Completion Date

November 5, 2020

Conditions
Bacterial Vaginoses
Interventions
DRUG

Secnidazole

One dose

Trial Locations (9)

33016

Site 1005 - Investigational Research Center, Hialeah

33161

Site 1001 - Investigational Research Center, Miami Lakes

33613

Site 1013, Tampa

34239

Site 1010 - Investigational Research Center, Sarasota

38104

Site 1007 - Investigational Research Center, Memphis

40004

Site 1011 - Investigational Research Center, Bardstown

48604

Site 1008 - Investigational Research Center, Saginaw

75035

Site 1006 - Investigational Research Center, Frisco

90806

Site 1004 - Investigational Research Center, Long Beach

Sponsors

Lead Sponsor

Lupin Research Inc
All Listed Sponsors
lead

Lupin Research Inc

INDUSTRY

NCT03937869 - Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV | Biotech Hunter | Biotech Hunter